Difference between revisions of "Periampullary adenocarcinoma"
Warner-admin (talk | contribs) m (Text replacement - "#66CCFF" to "#deebf6") |
Warner-admin (talk | contribs) m (Text replacement - "font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br>" to "font-size:300%"> Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br>") |
||
Line 1: | Line 1: | ||
{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | {|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | ||
| | | | ||
− | <span style="font-family:Arial; font-size: | + | <span style="font-family:Arial; font-size:300%"> Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br> |
− | |||
− | |||
'''Link:''' http://j.mp/2BlBaoQ | '''Link:''' http://j.mp/2BlBaoQ | ||
</span> | </span> |
Revision as of 04:27, 23 January 2018
Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful. |
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Section editor | |
---|---|
Neeta K. Venepalli, MD, MBA Chicago, IL |
0 regimens on this page
0 variants on this page
|
Liver cancer or hepatobiliary cancer comprises cancers that arise within the liver and its hepatocytes (hepatocellular carcinoma) and the biliary tract cancers, which include bile duct cancer/cholangiocarcinoma and gallbladder cancer.
Guidelines
ESMO
- 2016: Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. PubMed
NCCN
Adjuvant therapy
Placebo
back to top |
Regimen
Study | Evidence | Comparator | Efficacy |
---|---|---|---|
Neoptolemos et al. 2012 (ESPAC-3) | Phase III (C) | 5-FU & Leucovorin Gemcitabine |
Seems not superior |
Preceding treatment
- Surgery
Treatment
References
- Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012 Jul 11;308(2):147-56. Erratum in: JAMA. 2012 Nov 14;308(18):1861. link to original article PubMed